December 5, 2025 10:15am

CAPR is trading +1.00 at $26.32

The offering to close on or about 12/8/25.

CAPR believes these pivotal study results, in addition to the evidence from the HOPE-2 and HOPE-2 OLE studies, position … clinical issues in the FDA’s Complete Response Letter received earlier this year, consistent with prior FDA guidance that HOPE-3 results should be sufficient to support regulatory approval.” However, there are significant execution and regulatory risks around Deramiocel, including shifting FDA guidance and development costs.

Also, a 30-day option to purchase up to an additional 900,000 shares less the underwriting discounts and commissions. The gross proceeds from the offering are expected to be $150 M, before deducting underwriting discounts and commissions and offering expenses

Piper Sandler and Oppenheimer & Co. are acting as the joint book-running managers for the public offering. H.C. Wainwright & Co. is acting as the co-manager for the public offering.

 

The Bottom Line: I am a Sceptic on this CAPR financing???

  • I STILL SMELL an up pricing "scam", after Wednesday's +$23.60 per share "sprint"?

52-week range: $4.30 to $40.37 

My issue stock traded at $6.36 (12/3)and then jumped to $29.96 (12/4)

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
  • Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

 

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

 

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.